Cycloastragenol
The purified active fraction of astragaloside IV, sold as a telomerase activator. Expensive, and the human evidence does not come close to matching the price.
Cycloastragenol quick facts
| Suggested dose | Studied at 5–25 mg daily. Products vary enormously in actual content. |
| How often | Daily |
| Who it's for | Very hard to justify on current evidence, particularly at the price. |
This is the entry that most deserves a plain caution. Telomerase activation is exactly what a cancer cell needs to become immortal — around 90% of human cancers upregulate it — so the question of whether extending telomeres in somatic tissue is desirable is genuinely open rather than rhetorical. It is presented as unambiguously beneficial almost everywhere it is sold, and it is not. Expensive, and the human data is thin in both directions.
How Cycloastragenol actually works
An astragalus-derived saponin that activates telomerase, the enzyme rebuilding the telomeric caps that shorten with each cell division. It is the active behind TA-65. Telomere attrition is a genuine hallmark of ageing, and cell-culture work confirms the activation is real.
Where to get Cycloastragenol
Find Cycloastragenol on iHerb →The evidence for Cycloastragenol
Graded by what exists behind each claim.
✅ Clinically validated
- A small double-blind study of the TA-65 formulation reported increased proportions of certain immune cell subsets and lengthening of the shortest telomeres. Industry-conducted, small, and not independently replicated.
- No human trial has shown a clinical outcome — not lifespan, not disease incidence, not function.
📊 Correlative data
- Shorter leukocyte telomeres are associated with mortality in cohorts. Whether lengthening them is beneficial or simply a marker is genuinely unresolved.
🧪 Theoretical / extrapolated benefits
- Transiently activates telomerase (hTERT) in cells. The theoretical concern is the mirror image of the theoretical benefit: telomerase activation is also a hallmark of cancer cells.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Cycloastragenol actually does
Cycloastragenol is the aglycone that is left when the sugars come off astragaloside IV, and that hydrolysis is a gut step rather than a manufacturing one for anybody eating the root. Astragalus membranaceus contains astragaloside IV, a cycloartane triterpene glycoside; removing its glucose and xylose gives cycloastragenol, which is the molecule with the telomerase activity. The glycoside is poorly absorbed, and its transport and bioavailability have been characterized directly Gu 2004.
The mechanism claimed is transcriptional upregulation of the catalytic subunit of telomerase. Telomerase is a ribonucleoprotein that adds TTAGGG repeats to chromosome ends using its own RNA template; the limiting component in a somatic cell is the catalytic subunit hTERT, which is transcriptionally silenced in most adult tissue. Cycloastragenol is reported to raise hTERT expression, apparently through MAPK-dependent signaling, and to restore telomerase activity in cells under stress Hong 2021.
Why that matters is the end-replication problem. DNA polymerase cannot copy the extreme 3' end of a linear chromosome, so each division shortens the telomere; when the shortest telomeres reach a critical length the cell recognizes an uncapped end as a double-strand break and enters replicative senescence through p53 and p21. Lengthening telomeres therefore postpones a specific and well-characterized cellular event.
The measurement that matters is not average telomere length and this is where the surrogate goes wrong. Senescence is triggered by the SHORTEST telomeres in a cell, not by the mean, so the biologically meaningful read-out is the percentage of critically short telomeres. Mean leukocyte telomere length by quantitative PCR — the measurement most consumer tests report — has poor reproducibility and correlates weakly with the quantity the biology cares about Schellnegger 2024.
And there is a second mechanism that may matter more than the telomere one. Cycloastragenol reduces senescence markers through NRF2 activation and suppression of nuclear factor kappa B in chondrocytes Zhang 2026, which is a senomorphic action rather than a telomere action, and would produce the same cell-culture appearance without touching a chromosome end.
Cell, rodent, human — and where it stops
This is the purest surrogate on the page: the marker is telomere length, one trial moved a component of it, and no outcome trial exists in any species at a supplemental dose.
In cells the telomerase activation reproduces. Cycloastragenol and astragaloside IV activate telomerase and protect nucleus pulposus cells from high-glucose-induced senescence and apoptosis Hong 2021, and the senescence-restoring effect appears in chondrocytes through a different pathway Zhang 2026. The cell-culture case is consistent.
In humans there is one placebo-controlled trial and it is small. A randomized, double-blind, placebo-controlled study reported that a natural product telomerase activator lengthened telomeres in humans Salvador 2016, following an earlier open-label report of the same product used inside a health maintenance program Harley 2011. That is the entire human interventional literature for this molecule.
The obstacle to transfer is that the primary endpoint was a telomere measurement. The trial reported change in the proportion of short telomeres rather than a clinical outcome, and the earlier study was an open-label program with multiple concurrent interventions Harley 2011. Nobody has followed a supplemented person to a health event, a functional measure or a mortality endpoint.
And whether the marker predicts anything is itself contested. The review of telomeres as a longevity target is explicit that measurement methods vary, that mean leukocyte telomere length is a noisy proxy, and that the causal direction between telomere attrition and aging is not settled Schellnegger 2024. Moving a marker whose own prognostic value is argued is two inferential steps from a health claim.
The step that cannot be waved past is the oncology one. Telomerase is reactivated in roughly 85 to 90 percent of human cancers and is one of the enabling characteristics of malignancy; the relationship between aging, inflammation and telomerase is reviewed with that tension stated plainly Boccardi 2024. Any compound whose mechanism is systemic telomerase induction inherits that question.
Cycloastragenol — which form, and does it matter
Three materials are sold under adjacent names and only one has the human trial. Astragalus root extract, standardized astragaloside IV, and isolated cycloastragenol are three different products; the human trial used a specific proprietary preparation Salvador 2016. A generic astragalus capsule contains polysaccharides and astragalosides in unstated proportions and very little free aglycone.
The glycoside-to-aglycone step is the form question, and it is microbial for anybody taking the root. Astragaloside IV is a large polar triterpene glycoside with poor membrane permeability and documented low oral bioavailability, and it is a P-glycoprotein substrate that is pumped back into the lumen Gu 2004. Gut bacterial glycosidases remove the sugars to give cycloastragenol, which is smaller, more lipophilic and better absorbed — the same microbial-activation pattern the berberine and urolithin pages describe.
The exposure numbers are unfavorable and they explain the price. Oral bioavailability of astragaloside IV in animal work is well under 5 percent; cycloastragenol is better absorbed but undergoes extensive first-pass metabolism by cytochrome P450 hydroxylation followed by glucuronidation and sulfation, with biliary rather than renal clearance carrying most of the conjugates. Peak plasma concentration arrives within roughly 1 to 2 hours and the terminal half-life is a few hours.
Which means the exposure is short and the claimed effect is cumulative. A compound cleared in hours acting on a process measured in years implies either a transcriptional effect that persists between doses or no effect at all, and nobody has distinguished those. The human trial dosed daily for a year Salvador 2016.
What no label states and should. Milligrams of cycloastragenol per serving, verified by chromatography, and whether the material is the isolated aglycone or a standardized astragaloside extract. Products in this category are among the most expensive in the catalog and among the least specified.
What would have to be true, and how you would know it was not
1. Predict the telomere test moves within its own noise. Predict that telomere length measured by quantitative PCR changes by less than the assay's test-retest variability over 12 months, and that two samples taken on the same day differ measurably Schellnegger 2024. Run a duplicate baseline before believing any follow-up result.
2. Predict the proportion of short telomeres is the only endpoint worth measuring. The trial's reported effect was on the percentage of critically short telomeres rather than on the mean Salvador 2016. Predict that a consumer test reporting mean leukocyte telomere length cannot detect what the trial found.
3. The prediction that cuts against the product. Predict that no randomized trial links cycloastragenol to a clinical outcome — not function, not disease incidence, not mortality — because none exists Harley 2011 Schellnegger 2024. A trial reporting a functional or clinical endpoint would falsify this page and would be the first real evidence for the category.
4. Predict inflammatory and immune markers are where an effect would show first if there is one. Predict changes in lymphocyte subsets and in CD4/CD8 ratio over 12 months, because immune cells divide most and would be the first tissue to reflect a telomerase effect Boccardi 2024. Predict hs-CRP unchanged.
5. Predict that the senescence effect, if real, does not need telomerase. Predict that a senomorphic mechanism through NRF2 and nuclear factor kappa B could produce the cell-culture findings without any telomere change Zhang 2026. A study separating the two would either rescue the mechanism or reassign it.
What nobody has tested yet
The human evidence is one small trial and has never been replicated. A single randomized, placebo-controlled study Salvador 2016 supports an entire commercial category. An independent replication with the proportion of short telomeres as the prespecified primary endpoint is the study this field needs and does not have.
Nobody knows whether lengthening telomeres helps. The causal direction between telomere attrition and aging outcomes is unsettled, and Mendelian randomization work on genetically determined telomere length has produced findings in both directions for different diseases Schellnegger 2024. Longer is not automatically better.
The cancer question has never been addressed prospectively. Telomerase reactivation is a hallmark of malignancy Boccardi 2024, and no trial of a telomerase activator has been powered or long enough to detect a change in cancer incidence. That is the largest unresolved risk on this page and it is unresolved in both directions: longer telomeres in a healthy cell may equally prevent the genomic instability that starts a cancer.
And the market has never been assayed. No published survey has bought commercial cycloastragenol products and reported cycloastragenol content by chromatography against label claim Gu 2004. For a product at this price point, that is a conspicuous absence.
Cycloastragenol — its own safety story, not its category's
Short-term tolerability in the one trial was unremarkable, and that is a limited statement. The randomized study reported no significant adverse event signal over its duration Salvador 2016. Twelve months in a small sample cannot detect the risk that matters here.
The theoretical concern is the mechanism, and it deserves to be stated first rather than last. Telomerase activity is one of the enabling characteristics of cancer and is reactivated in the large majority of human tumors Boccardi 2024. A systemic telomerase activator taken indefinitely by a healthy person is an experiment whose relevant endpoint takes decades to appear, and nobody is running it.
Anyone with a current or prior malignancy should treat this as an oncology conversation. The concern is specific rather than generic: the proposed mechanism is the same one a tumor uses to escape replicative limits.
The interaction profile follows from the metabolism and is unquantified. Cycloastragenol is metabolized by cytochrome P450 and is a P-glycoprotein substrate Gu 2004, so interactions with CYP3A4 substrates and P-glycoprotein inhibitors are plausible and have not been studied clinically. Astragalus preparations more broadly have immunostimulant activity, which matters in autoimmune disease and after transplant.
Who this is not established for, which is everybody. Pregnancy and lactation, with no data. Anyone with an autoimmune condition or on an immunosuppressant. Anyone with a cancer history. And anyone buying a telomere test to judge the result, who should know the assay cannot reliably measure what the trial measured Schellnegger 2024. Nothing here is medical advice or diagnosis, and these statements have not been evaluated by the Food and Drug Administration.
Sources read for this page
- Salvador L, et al. A Natural Product Telomerase Activator Lengthens Telomeres in Humans: A Randomized, Double Blind, and Placebo Controlled Study. Rejuvenation Research 2016 · PMID 26950204
- Harley CB, et al. A natural product telomerase activator as part of a health maintenance program. Rejuvenation Research 2011 · PMID 20822369
- Schellnegger M. Unlocking longevity: the role of telomeres and its targeting interventions. Front Aging 2024 · PMID 38333665
- Hong H. Cycloastragenol and Astragaloside IV activate telomerase and protect nucleus pulposus cells against high glucose-induced senescence and apoptosis. Exp Ther Med 2021 · PMID 34630680
- Boccardi V. Aging, Cancer, and Inflammation: The Telomerase Connection. Int J Mol Sci 2024 · PMID 39126110
- Gu Y, et al. Transport and bioavailability studies of astragaloside IV, an active ingredient in Radix Astragali. Basic & Clinical Pharmacology & Toxicology 2004 · PMID 15569275
- Zhang S. Cycloastragenol attenuates osteoarthritis by restoring chondrocyte senescence via the NRF2/NF-kappaB signaling axis. Sci Rep 2026 · PMID 41813816
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: Nothing, and it is the most expensive nothing on this shelf. No human trial has shown a clinical outcome for it — not lifespan, not disease incidence, not function — so there is no symptom to score. The read-out being sold is telomere length, which means a test bought from a consumer lab whose results vary enough between runs that one person's change cannot be interpreted.
- How long before it means anything: There is no window. Telomere attrition is measured across years in cohorts, and whether lengthening telomeres is beneficial or merely a marker of something else is genuinely unresolved — so even a real change would not tell you what you were hoping to learn.
- What will fool you: The mirror image of the mechanism. Telomerase activation is the selling point and it is also a hallmark of cancer cells; animal studies have not shown more tumors, which is reassuring rather than decisive, and long-term human safety data does not exist. Add that products vary enormously in actual content, and a null result may mean the capsule was empty. If a longevity budget is the question, the cheap end of this shelf has better data behind it.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Cycloastragenol — safety & side effects
- Well tolerated in the limited human data.
- The telomerase question is the honest one: activating telomerase is the mechanism, and whether that carries a cancer risk in humans is unresolved rather than dismissed. The animal data are reassuring; the human data do not exist at the duration that would matter.
- Immunostimulant — caution with autoimmune disease and immunosuppressants.
The same on every page it applies to. Read it here; it is not repeated research.
- Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Cycloastragenol in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Cycloastragenol
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | The inflammation these are aimed at |
| ApoB (Apolipoprotein B) | Cardiovascular risk, measured properly |
| HbA1c (Hemoglobin A1c) | Glycation over three months |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
The Longevity Baseline panel covers these in one order — 13 markers, $219.10 with the discount applied.
Check results you already have → · All 103 markers A–Z
Cycloastragenol — frequently asked questions
What is Cycloastragenol?
The purified active fraction of astragaloside IV, sold as a telomerase activator. Expensive, and the human evidence does not come close to matching the price.
What is the suggested dose of Cycloastragenol?
Studied at 5–25 mg daily. Products vary enormously in actual content. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Cycloastragenol dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Cycloastragenol?
Coach Cam sources Cycloastragenol from vetted, top-rated brands on iHerb — use the buy link on this page.
What Cycloastragenol is used for
Cycloastragenol appears under 1 goal in the goal router.
Related Longevity & Antioxidants supplements
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.